Outcomes of unselected patients with pathologic T3N0 rectal cancer

被引:11
|
作者
Kennecke, Hagen [1 ]
Lim, Howard [1 ]
Woods, Ryan [1 ]
McGahan, Colleen E. [1 ]
Hay, John [1 ]
Raval, Manoj J. [2 ]
Johal, Balvinder [3 ]
机构
[1] Vancouver Ctr, Vancouver, BC, Canada
[2] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[3] Fraser Valley Canc Ctr, Vancouver, BC, Canada
关键词
Rectal cancer; Trimodality therapy; Locoregional recurrence; Disease-specific survival; SHARP MESORECTAL EXCISION; NO ADJUVANT THERAPY; PREOPERATIVE RADIOTHERAPY; POSTOPERATIVE CHEMORADIOTHERAPY; CHEMOTHERAPY; RADIATION; SURVIVAL; RISK;
D O I
10.1016/j.radonc.2012.09.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: This study compares the outcomes of patients with pathological (p) T3N0 rectal cancer treated with surgery alone (S), surgery and radiation (SR) or surgery, radiation and chemotherapy (SRC), in a population based setting. Materials: Three hundred and seven patients with operable, macroscopically resected pT3N0 rectal cancer referred to the BC Cancer Agency between 2000 and 2004 were segregated by treatment type: S (n = 65), SR (n = 97) and SRC (n = 145). Patient characteristics, 5-year locoregional recurrence (LRR) and disease-specific survival (DSS) were compared between treatment cohorts. Results: Median age differed significantly between S, SR and SRC patient cohorts: 76, 72 and 64 years respectively. Five-year LRR differed by treatment group, with 29% for S, 6.3% for SR and 3.84% for SRC patients. DSS was superior in SRC compared to S patients (hazard ratio = 031 [0.17, 0.60]). Co-morbidities and patient preference were most common reasons for omission of radiation. Conclusions: Unselected patients with pT3N0 rectal cancer not treated with pen-operative radiation experience a high rate of LRR and reduced DSS in comparison to patients treated with bimodality and tri-modality therapies. Advanced age is significantly associated with omission of therapy in patients with early stage rectal cancer. (C) 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 105 (2012) 214-219
引用
收藏
页码:214 / 219
页数:6
相关论文
共 50 条
  • [21] Vascular endothelial growth factor as a potential prognostic factor for T3N0 rectal cancer
    Sekulic, Aleksandar
    Barisic, Goran
    Dundjerovic, Dusko
    Tatic, Svetislav
    Krivokapic, Zoran
    VOJNOSANITETSKI PREGLED, 2020, 77 (02) : 189 - 195
  • [22] Depth of Mesorectal Invasion has Prognostic Significance in T3N0 Low Rectal Cancer
    Tokoro, Tadao
    Okuno, Kiyotaka
    Hida, Jin-ichi
    Ishimaru, Eizaburo
    Ueda, Kazula
    Yoshifuji, Takehito
    HEPATO-GASTROENTEROLOGY, 2009, 56 (89) : 124 - 127
  • [23] Does Adjuvant Chemotherapy Improve Survival in T3N0 Rectal Cancer? An Evaluation of Use and Outcomes from the National Cancer Database
    de Paula, Thais Reif
    Keller, Deborah S.
    Gorroochurn, Prakash
    Kiran, Ravi P.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : S58 - S58
  • [24] Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers
    Olga A. Lavryk
    Elena Manilich
    Michael A. Valente
    Arshiya Miriam
    Emre Gorgun
    Matthew F. Kalady
    Sherief Shawki
    Conor P. Delaney
    Scott R. Steele
    International Journal of Colorectal Disease, 2020, 35 : 77 - 84
  • [25] SEER-based Analysis of the Impact of Preoperative or Postoperative Radiation Therapy on Survival Outcomes for T3N0 Rectal Cancer
    Peng, L.
    Coplowitz, S.
    Parashar, B.
    Nori, D.
    Chao, K.
    Wernicke, A. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S345 - S346
  • [26] Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers
    Lavryk, Olga A.
    Manilich, Elena
    Valente, Michael A.
    Miriam, Arshiya
    Gorgun, Emre
    Kalady, Matthew F.
    Shawki, Sherief
    Delaney, Conor P.
    Steele, Scott R.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (01) : 77 - 84
  • [27] Does Adjuvant Chemotherapy Improve Survival in T3N0 Rectal Cancer? An Evaluation of Use and Outcomes from the National Cancer Database (NCDB)
    Thais Reif de Paula
    Prakash Gorroochurn
    Ravi P. Kiran
    Deborah S. Keller
    Journal of Gastrointestinal Surgery, 2020, 24 : 1188 - 1191
  • [28] Exploring the Potential Different Outcomes Associated With the Different Phenotypes Under the Shared Pathologic T3N0 Designation
    Peng, Terrance
    Wightman, Sean C.
    Ding, Li
    Atay, Scott M.
    Alicuben, Evan T.
    David, Elizabeth A.
    Kim, Anthony W.
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [29] Does Adjuvant Chemotherapy Improve Survival in T3N0 Rectal Cancer? An Evaluation of Use and Outcomes from the National Cancer Database (NCDB)
    de Paula, Thais Reif
    Gorroochurn, Prakash
    Kiran, Ravi P.
    Keller, Deborah S.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2020, 24 (05) : 1188 - 1191
  • [30] A critical appraisal of treatment for T3N0 colon cancer
    Yo, IS
    Opelka, FG
    Bolton, JS
    Fuhrman, GM
    AMERICAN SURGEON, 2001, 67 (02) : 143 - 148